Koob George F, Kenneth Lloyd G, Mason Barbara J
Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, 10550 North Torrey Pines Road, SP30-2400 La Jolla, California 92037, USA.
Nat Rev Drug Discov. 2009 Jun;8(6):500-15. doi: 10.1038/nrd2828.
Current pharmacotherapies for addiction represent opportunities for facilitating treatment and are forming a foundation for evaluating new medications. Furthermore, validated animal models of addiction and a surge in understanding of neurocircuitry and neuropharmacological mechanisms involved in the development and maintenance of addiction - such as the neuroadaptive changes that account for the transition to dependence and the vulnerability to relapse - have provided numerous potential therapeutic targets. Here, we emphasize a 'Rosetta Stone approach', whereby existing pharmacotherapies for addiction are used to validate and improve animal and human laboratory models to identify viable new treatment candidates. This approach will promote translational research and provide a heuristic framework for developing efficient and effective pharmacotherapies for addiction.
目前用于成瘾治疗的药物疗法为促进治疗提供了机会,并正在为评估新药奠定基础。此外,经过验证的成瘾动物模型以及对成瘾发展和维持过程中涉及的神经回路和神经药理学机制(例如导致向依赖转变和易复发的神经适应性变化)的深入理解,提供了众多潜在的治疗靶点。在此,我们强调一种“罗塞塔石碑方法”,即利用现有的成瘾药物疗法来验证和改进动物及人体实验室模型,以识别可行的新治疗候选药物。这种方法将促进转化研究,并为开发高效且有效的成瘾药物疗法提供一个启发式框架。